First Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Belinostat in Patients with R/R PTCL in Brazil (BELBRA)

Introduction: Belinostat (BEL) is a Pan-Histone Deacetylase Inhibitors (HDACi) that increases histone acetylation leading with anti-angiogenic and antitumor properties indicated in the treatment of in refractory or relapsed (R/R) Peripheral T-Cell Lymphoma (PTCL). BELBRA is the real-life observatory study initiated in Brazil with the participation of 90 lymphoma reference centers, with 97 patients to date.

Methods and Aims: To date, 97 R/R PTCL patients treated with Belinostat in Brazil have been identified. In this interim analysis, the demographic characteristics of the patients were analyzed. Furthermore, more detailed analyzes of 20 patients were carried out. Data collection and statistical analyzes continue to be conducted.

Results: The interim results of the BELBRA study, focus on the efficacy and safety of Belinostat (BEL) in treating R/R PTCL. The cohort demonstrated a diverse range of PTCL subtypes, with a majority being lymphoma NOS. Treatment primarily included CHOP or similar therapies, with Belinostat administered in later lines. The study reports a 45% overall response rate, stable disease in 10%, and disease progression in 45% of the detailed cohort, with treatments being well tolerated across an average of 5 cycles. No other AE´s than the Belief Study was observed.

Conclusion: These findings highlight Belinostat's potential as a favorable option for PTCL patients resistant to previous treatments, contributing as valuable real-world evidence to these challenging patients.

O'Connor:Acrotec: Honoraria, Other: Advisor; Kymera: Current equity holder in publicly-traded company, Honoraria, Other: Scientific advisory board; Dren Bio: Current equity holder in publicly-traded company; Myeloid Therapeutics: Current equity holder in publicly-traded company, Honoraria; BMS: Research Funding; Merck: Research Funding.